Evidence map›Paper›PMID 38542254›Full record

ArticleInternational journal of molecular sciences2024

ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression.

Yolanda María Guillén-Pérez, María Jesús Ortiz-Ruiz, Javier Márquez, Atanasio Pandiella, Azucena Esparís-Ogando

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. VCAN Is Essential for ERK5-Driven Tumorigenesis in Soft Tissue Sarcoma.International journal of biological sciences · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yolanda María Guillén-PérezInstituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0009-0006-5716-5414
María Jesús Ortiz-RuizInstituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain.
Javier MárquezCanceromics Laboratory, Departamento de Biología Molecular y Bioquímica, Universidad de Málaga, 29010 Málaga, Spain.ORCID 0000-0003-3317-3963
Atanasio PandiellaInstituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-4704-8971
Azucena Esparís-OgandoInstituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0003-4550-4192
Consejo Superior de Investigaciones Científicas · ESInstituto de Investigación Biomédica de Málaga · ES

Funding

Instituto de Salud Carlos III PI15/01180 and PI19/00840
6 · The paper itself

Abstract

Many of the biological processes of the cell, from its structure to signal transduction, involve protein-protein interactions. On this basis, our aim was to identify cellular proteins that interact with ERK5, a serine/threonine protein kinase with a key role in tumor genesis and progression and a promising therapeutic target in many tumor types. Using affinity chromatography, immunoprecipitation, and mass spectrometry techniques, we unveiled an interaction between ERK5 and the mitochondrial glutaminase GLS in pancreatic tumor cells. Subsequent co-immunoprecipitation and immunofluorescence studies supported this interaction in breast and lung tumor cells as well. Genetic approaches using RNA interference techniques and CRISPR/Cas9 technology demonstrated that the loss of ERK5 function led to increased protein levels of GLS isoforms (KGA/GAC) and a concomitant increase in their activity in tumor cells. It is well known that the tumor cell reprograms its intermediary metabolism to meet its increased metabolic needs. In this sense, mitochondrial GLS is involved in the first step of glutamine catabolism, one of the main energy sources in the context of cancer. Our data suggest that ERK5 contributes to the regulation of tumor cell energy metabolism via glutaminolysis.

Indexed as

GlutaminaseLung NeoplasmsCell Line, TumorGlutamineHumansMitochondriaRNA InterferenceSignal TransductionGlutaminaseGlutaminecancer therapyenergy metabolismERK5GLS isoformsglutaminasemitochondriaproteomics

Identifiers

PMID38542254
PMCPMC10970367
OpenAlexW4392817088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.